Search

Your search keyword '"ANTIRESORPTIVES"' showing total 356 results

Search Constraints

Start Over You searched for: Descriptor "ANTIRESORPTIVES" Remove constraint Descriptor: "ANTIRESORPTIVES" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
356 results on '"ANTIRESORPTIVES"'

Search Results

1. A retrospective audit with subsequent cost and environmental analysis of a denosumab self-injection program.

2. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures.

Catalog

Books, media, physical & digital resources

3. Implications in dental treatment during the use of antiresorptive drugs - a literature review

4. Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective.

5. Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study.

6. On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal.

7. Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk

8. Denosumab and Mortality in a Real‐World Setting: A Comparative Study.

9. No Effect of NSAID Use on Efficacy of Zoledronate: A Post Hoc Analysis of a Randomized Trial in Osteopenic Older Women.

10. Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study

11. RISCO DE OSTEONECROSE EM PACIENTES QUE FAZEM USO DE ANTIRREABSORTIVOS E INSTALAÇÃO DE IMPLANTES.

12. Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study.

13. The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial

14. A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

15. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence

16. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.

17. Bisphosphonates Preserve Bone Mineral Density and Suppress Bone Turnover Markers in Early Menopausal Women: A Systematic Review and Meta‐Analysis of Randomized Trials.

18. Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study

19. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials

20. Bisphosphonates Preserve Bone Mineral Density and Suppress Bone Turnover Markers in Early Menopausal Women: A Systematic Review and Meta‐Analysis of Randomized Trials

21. A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome.

22. TRACP‐5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.

23. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.

24. Denosumab for Prevention of Acute Onset Immobilization‐Induced Alterations of Bone Turnover: A Randomized Controlled Trial.

25. Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women.

26. Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity.

27. Use and risk of side effects of antiresorptive medication in people with intellectual disabilities [version 1; peer review: 2 approved]

28. TRACP‐5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia

29. Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self‐Controlled Case Series in the United Kingdom.

30. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review

31. Target Values and Daytime Variation of Bone Turnover Markers in Monitoring Osteoporosis Treatment After Fractures.

32. Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses.

33. Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs.

34. Real‐World Effectiveness of Anti‐Resorptive Treatment in Patients With Incident Fragility Fractures—The STORM Cohort—A Swedish Retrospective Observational Study.

35. Target Values and Daytime Variation of Bone Turnover Markers in Monitoring Osteoporosis Treatment After Fractures

36. Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses

37. Bisphosphonate Treatment Alters the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta: A Pilot Study.

38. Denosumab in Cementless Total Hip Arthroplasty: Multivariate Reanalysis of 3D Femoral Stem Migration and the Influence on Outliers.

39. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.

40. Bisphosphonate Use May Reduce the Risk of Urolithiasis in Astronauts on Long‐Term Spaceflights.

41. Fracture Risk Following an Atypical Femoral Fracture.

42. The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.

43. Bisphosphonate Treatment Alters the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta: A Pilot Study

44. Denosumab in Cementless Total Hip Arthroplasty: Multivariate Reanalysis of 3D Femoral Stem Migration and the Influence on Outliers

45. Bisphosphonate Use May Reduce the Risk of Urolithiasis in Astronauts on Long‐Term Spaceflights

46. Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.

47. Sequential Therapy With Recombinant Human IGF‐1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo‐Controlled Trial.

48. Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?

49. Early inhibition of subchondral bone remodeling slows load‐induced posttraumatic osteoarthritis development in mice.

50. Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases.